In proliferating MCF-7 cells exposed to ZM-447439 for 72 h, cloning efficiency was reduced to below 40% at 1.25 μM and 2.5 μM. In HeLa cells treated with MPS1-IN-1 followed by ZM-447439, the slope of kinetochore Dsn1S109ph versus distance from the midzone differed significantly between control and ZM-447439-treated cells (p < 0.0001, F test). In HT1080 cells carrying an autonomously propagated EGFP-HAC, treatment at 1 μM for 3 days yielded 70.4 ± 0.5% cells with EGFP. Following a 12-h nocodazole block, 4% of mitotic HeLa cells treated with 2 μM ZM-447439 remained in mitosis after 1 h, compared with 67% of controls. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Reduced Cloning Efficiency in Proliferating MCF-7 Cells
Cell-based study · proliferating MCF-7 cells [1]
Proliferating MCF-7 cells were exposed to ZM-447439 for 72 h. At 1.25 μM and 2.5 μM, cloning efficiency was reduced to below 40%.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1.25 μM and 2.5 μM
- Exposure duration
- exposed to ZM447439 for 72 h
- Method
- ZM447439 was then added
- Vehicle
- DMSO
Methods and source locations
Compound reported in the paper: ZM-447439
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > ZM447439-induced endoreduplication is enhanced in the absence of p53 function (S21); Materials and methods > Cell culture (S141); Materials and methods > Cell cycle analysis and cloning assays (S147, S149, S150); Figure 2. legend (S179)
cloning efficiency: cloning efficiency; comparator: DMSO-treated controls — Results > ZM447439-induced endoreduplication is enhanced in the absence of p53 function (S21); Materials and methods > Cell cycle analysis and cloning assays (S150)
Kinetochore Phosphorylation Gradient in HeLa Cells
Cell-based study · HeLa cells [2]
HeLa cells were treated with MPS1-IN-1 and then with 10 μM ZM447439 for 15 min, prior to fixation. For ZM447439-treated cells, slope = 0.12 and is not significantly different from zero (p = 0.48). The slopes are significantly different from one another (p < 0.0001, F test).
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 μM
- Exposure duration
- for 15 min, prior to fixation
- Co-treatment
- Other interventions in this design: MPS1-IN-1 10 μM. Compound effect isolated by the comparison: nine control and five ZM447439-treated cells.
- Reported limits
- Not stated in the sentences used: route, vehicle. Removed after verification: value.
Methods and source locations
Compound reported in the paper: ZM-447439
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Anaphase phosphorylation of Dsn1 requires the central spindle-dependent gradient of Aurora B activity (S25, S28, S29); STAR★Methods > Method details > Cell treatments (S156); Figure 2 legend (S200, S203)
Dsn1S109ph at individual kinetochores as a function of distance from the midzone: Dsn1S109ph at individual kinetochores as a function of distance from the midzone; comparator: nine control — Results > Anaphase phosphorylation of Dsn1 requires the central spindle-dependent gradient of Aurora B activity (S25, S28, S29); Figure 2 legend (S200, S203)
EGFP Readout in Cells Carrying an Autonomously Propagated HAC
Cell-based study · HT1080 cells with an autonomously propagated EGFP-HAC [3]
HT1080 cells with an autonomously propagated EGFP-HAC were treated at 1 μM for 3 days. The proportion of cells with EGFP was 70.4 ± 0.5%.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 μM
- Exposure duration
- 3 days
- Reported limits
- Not stated in the sentences used: route, vehicle.
Methods and source locations
Compound reported in the paper: ZM-447439
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Effect of aneugens and clastogens on the rate of HAC mis-segregation during mitotic divisions (S120); Table 1 (T1.h1, T1.r12); Table 3 (T3.h2, T3.r1, T3.r10)
% Cells with EGFP: % Cells with EGFP; comparator: No drug — Table 1 (T1.r12); Table 3 (T3.h2, T3.r10)
Mitotic Index in HeLa Cells Following Nocodazole Block
Cell-based study · Mitotic HeLa cells [1]
Mitotic HeLa cells received 2 μM ZM-447439 following a 12-h nocodazole block. After 1 h, only 4% of ZM-447439-treated cells remained in mitosis, compared with 67% of controls.
Literature-Reported Treatment Conditions
- Treatment concentration
- 2 μM
- Exposure duration
- after a 12-h nocodazole block; after 1 h
- Method
- replated in various drug combinations
- Vehicle
- DMSO
- Co-treatment
- Other interventions in this design: nocodazole. Compound effect isolated by the comparison: only 4% of the ZM447439-treated cells were still in mitosis, compared with 67% of the controls.
Methods and source locations
Compound reported in the paper: ZM-447439
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > ZM447439 compromises spindle checkpoint function (S56, S63); Materials and methods > Cell culture (S141, S143, S144); Figure 5. legend (S199, S201)
mitotic index, as determined by MPM-2 reactivity: mitotic index, as determined by MPM-2 reactivity; comparator: controls — Results > ZM447439 compromises spindle checkpoint function (S63); Materials and methods > Cell culture (S143); Figure 5. legend (S199, S201)
